{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:21:59Z","timestamp":1787732519724,"version":"build-2784847793"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA278100"],"award-info":[{"award-number":["5R01CA278100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA159981"],"award-info":[{"award-number":["P50CA159981"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemotherapy remains the primary treatment for ovarian cancer (OvCa), and chemoresistance drives patient mortality. Cellular quiescence, reversible exit from the cell cycle, increases chemotherapy resistance as chemotherapies primarily target rapidly proliferating cells. Here, we report that CHD4 and MBD3, components of the nucleosome remodeling and deacetylase (NuRD) complex, are downregulated in quiescent OvCa cells (qOvCa). We find that either CHD4 or MBD3 knockdown or histone deacetylase inhibitors (HDACi), induce quiescence in OvCa cells. RNA-Seq and ATAC-seq analysis of HDACi-treated cells confirmed expression changes consistent with induction of quiescence. Additionally, HDACi-treated cells revealed downregulation of the RHO\/RAC pathways. Suggesting downregulation of the RAC pathway could play a role in HDACi-mediated quiescence, RAC inhibitors (RACi) similarly induced quiescence. Both HDACi and RACi resulted in nuclear-to-cytoplasmic shifting of the pro-proliferative transcription factor MRTFA. which has been linked to quiescence. Further analysis of HDACi qOvCa indicated multiple alterations in proteostasis, including increased proteasome activity and autophagy. We find qOvCa cells are dependent on these pathways for survival, such that there is profound synergistic OvCa cell death with HDACi and proteasome- or autophagy-inhibitor combination therapy. Combined, this work supports HDACi as pharmacologic means to induce a quiescent state in OvCa cells and sensitize them to proteostasis-targeting drugs.<\/jats:p>","DOI":"10.1038\/s41417-026-01067-y","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:41:05Z","timestamp":1786603265000},"page":"1053-1068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting HDAC and proteostasis to eradicate quiescent cancer cells"],"prefix":"10.1038","volume":"33","author":[{"given":"Qi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Arrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Hijazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-9917","authenticated-orcid":false,"given":"Jennifer L.","family":"Goeckeler-Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Sagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Beddows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy Ann","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-9514","authenticated-orcid":false,"given":"Daniel D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Stallaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-2560","authenticated-orcid":false,"given":"Amanda M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9767-4084","authenticated-orcid":false,"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-8486","authenticated-orcid":false,"given":"Jeffrey L.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-1777","authenticated-orcid":false,"given":"Hatice U.","family":"Osmanbeyoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-9790","authenticated-orcid":false,"given":"Ronald J.","family":"Buckanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1067_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","DOI":"10.3322\/caac.21834"},{"key":"1067_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cca.2014.11.015","volume":"440","author":"AM Chudecka-G\u0142az","year":"2015","unstructured":"Chudecka-G\u0142az AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta. 2015;440:143\u201351.","journal-title":"Clin Chim Acta"},{"key":"1067_CR3","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1126\/science.287.5459.1804","volume":"287","author":"T Cheng","year":"2000","unstructured":"Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, et al. Hematopoietic stem cell quiescence maintained by p21cip1\/waf1. Science. 2000;287:1804\u20138.","journal-title":"Science"},{"key":"1067_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/cas.13917","volume":"110","author":"H Endo","year":"2019","unstructured":"Endo H, Inoue M. Dormancy in cancer. Cancer Sci. 2019;110:474\u201380.","journal-title":"Cancer Sci"},{"key":"1067_CR5","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1128\/MCB.23.24.9136-9149.2003","volume":"23","author":"V Ramaswamy","year":"2003","unstructured":"Ramaswamy V, Williams JS, Robinson KM, Sopko RL, Schultz MC. Global control of histone modification by the anaphase-promoting complex. Mol Cell Biol. 2003;23:9136\u201349.","journal-title":"Mol Cell Biol"},{"key":"1067_CR6","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/nar\/gkp270","volume":"37","author":"RM Friis","year":"2009","unstructured":"Friis RM, Wu BP, Reinke SN, Hockman DJ, Sykes BD, Schultz MC. A glycolytic burst drives glucose induction of global histone acetylation by picNuA4 and SAGA. Nucleic Acids Res. 2009;37:3969\u201380.","journal-title":"Nucleic Acids Res"},{"key":"1067_CR7","doi-asserted-by":"crossref","unstructured":"Flora P, Dalal G, Cohen I, Ezhkova E. Polycomb repressive complex(es) and their role in adult stem cells. Genes. 2021;12:1485.","DOI":"10.3390\/genes12101485"},{"key":"1067_CR8","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1101\/gad.1642808","volume":"22","author":"T Yoshida","year":"2008","unstructured":"Yoshida T, Hazan I, Zhang J, Ng SY, Naito T, Snippert HJ, et al. The role of the chromatin remodeler Mi-2beta in hematopoietic stem cell self-renewal and multilineage differentiation. Genes Dev. 2008;22:1174\u201389.","journal-title":"Genes Dev"},{"key":"1067_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/hdy.2010.54","volume":"105","author":"ER Gibney","year":"2010","unstructured":"Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity. 2010;105:4\u201313.","journal-title":"Heredity"},{"key":"1067_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203880","volume":"10","author":"S Vermeulen","year":"2022","unstructured":"Vermeulen S, Van Puyvelde B, Bengtsson Del Barrio L, Almey R, van der Veer BK, Deforce D, et al. Micro-topographies induce epigenetic reprogramming and quiescence in human mesenchymal stem cells. Adv Sci. 2022;10:e2203880.","journal-title":"Adv Sci"},{"key":"1067_CR11","doi-asserted-by":"publisher","first-page":"34400","DOI":"10.1074\/jbc.M112.390294","volume":"287","author":"J Hanna","year":"2012","unstructured":"Hanna J, Waterman D, Boselli M, Finley D. Spg5 protein regulates the proteasome in quiescence. J Biol Chem. 2012;287:34400\u20139.","journal-title":"J Biol Chem"},{"key":"1067_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.acr.2018.12.002","volume":"141","author":"S Talukdar","year":"2019","unstructured":"Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43\u201384.","journal-title":"Adv Cancer Res"},{"key":"1067_CR13","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.biocel.2012.08.022","volume":"44","author":"Z Yu","year":"2012","unstructured":"Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol. 2012;44:2144\u201351.","journal-title":"Int J Biochem Cell Biol"},{"key":"1067_CR14","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1111\/febs.13023","volume":"281","author":"S Colak","year":"2014","unstructured":"Colak S, Medema JP. Cancer stem cells\u2013important players in tumor therapy resistance. FEBS J. 2014;281:4779\u201391.","journal-title":"FEBS J"},{"key":"1067_CR15","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1080\/21691401.2019.1638793","volume":"47","author":"J Zhang","year":"2019","unstructured":"Zhang J, Si J, Gan L, Di C, Xie Y, Sun C, et al. Research progress on therapeutic targeting of quiescent cancer cells. Artif Cells Nanomed Biotechnol. 2019;47:2810\u201320.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1067_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bcp.2018.11.004","volume":"162","author":"FM Vallette","year":"2019","unstructured":"Vallette FM, Olivier C, L\u00e9zot F, Oliver L, Cochonneau D, Lalier L, et al. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochem Pharmacol. 2019;162:169\u201376.","journal-title":"Biochem Pharmacol"},{"key":"1067_CR17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fonc.2019.00626","volume":"9","author":"ML De Angelis","year":"2019","unstructured":"De Angelis ML, Francescangeli F, La Torre F, Zeuner A. Stem cell plasticity and dormancy in the development of cancer therapy resistance. Front Oncol. 2019;9:626.","journal-title":"Front Oncol"},{"key":"1067_CR18","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1158\/1078-0432.CCR-10-1499","volume":"17","author":"L Li","year":"2011","unstructured":"Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res. 2011;17:4936\u201341.","journal-title":"Clin Cancer Res"},{"key":"1067_CR19","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.2373","volume":"5","author":"ZC Dobbin","year":"2014","unstructured":"Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget. 2014;5:8750\u201364.","journal-title":"Oncotarget"},{"key":"1067_CR20","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/onc.2010.35","volume":"29","author":"MQ Gao","year":"2010","unstructured":"Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29:2672\u201380.","journal-title":"Oncogene"},{"key":"1067_CR21","doi-asserted-by":"crossref","unstructured":"Cole AJ, Iyengar M, Panesso-G\u00f3mez S, O\u2019Hayer P, Chan D, Delgoffe GM, et al. NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer. JCI Insight. 2020;5:e131486.","DOI":"10.1172\/jci.insight.131486"},{"key":"1067_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218435","volume":"646","author":"S Panesso-G\u00f3mez","year":"2026","unstructured":"Panesso-G\u00f3mez S, Cole AJ, Arrigo A, Roberts A, Bello M, Wield A, et al. Identification of the MRTFA\/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer. Cancer Lett. 2026;646:218435.","journal-title":"Cancer Lett"},{"key":"1067_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.trsl.2014.05.003","volume":"165","author":"J Basta","year":"2015","unstructured":"Basta J, Rauchman M. The nucleosome remodeling and deacetylase complex in development and disease. Transl Res. 2015;165:36\u201347.","journal-title":"Transl Res"},{"key":"1067_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1074\/mcp.M115.053207","volume":"15","author":"D Bode","year":"2016","unstructured":"Bode D, Yu L, Tate P, Pardo M, Choudhary J. Characterization of two distinct nucleosome remodeling and deacetylase (NuRD) complex assemblies in embryonic stem cells. Mol Cell Proteom. 2016;15:878\u201391.","journal-title":"Mol Cell Proteom"},{"key":"1067_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0938-8","volume":"17","author":"T Hashimshony","year":"2016","unstructured":"Hashimshony T, Senderovich N, Avital G, Klochendler A, de Leeuw Y, Anavy L, et al. CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq. Genome Biol. 2016;17:77.","journal-title":"Genome Biol"},{"key":"1067_CR26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrc3091","volume":"11","author":"AY Lai","year":"2011","unstructured":"Lai AY, Wade PA. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat Rev Cancer. 2011;11:588\u201396.","journal-title":"Nat Rev Cancer"},{"key":"1067_CR27","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-22-2254","volume":"29","author":"AJ Cole","year":"2023","unstructured":"Cole AJ, Panesso-G\u00f3mez S, Shah JS, Ebai T, Jiang Q, Gumusoglu-Acar E, et al. Quiescent ovarian cancer cells secrete follistatin to induce chemotherapy resistance in surrounding cells in response to chemotherapy. Clin Cancer Res. 2023;29:1969\u201383.","journal-title":"Clin Cancer Res"},{"key":"1067_CR28","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41592-022-01663-4","volume":"19","author":"M Pachitariu","year":"2022","unstructured":"Pachitariu M, Stringer C. Cellpose 2.0: how to train your own model. Nat Methods. 2022;19:1634\u201341.","journal-title":"Nat Methods"},{"key":"1067_CR29","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.7717\/peerj.453","volume":"2","author":"S van der Walt","year":"2014","unstructured":"van der Walt S, Sch\u00f6nberger JL, Nunez-Iglesias J, Boulogne F, Warner JD, Yager N, et al. scikit-image: image processing in Python. PeerJ. 2014;2:e453.","journal-title":"PeerJ"},{"key":"1067_CR30","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202211087","volume":"18","author":"W Stallaert","year":"2022","unstructured":"Stallaert W, Taylor SR, Kedziora KM, Taylor CD, Sobon HK, Young CL, et al. The molecular architecture of cell cycle arrest. Mol Syst Biol. 2022;18:e11087.","journal-title":"Mol Syst Biol"},{"key":"1067_CR31","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41587-019-0336-3","volume":"37","author":"KR Moon","year":"2019","unstructured":"Moon KR, van Dijk D, Wang Z, Gigante S, Burkhardt DB, Chen WS, et al. Visualizing structure and transitions in high-dimensional biological data. Nat Biotechnol. 2019;37:1482\u201392.","journal-title":"Nat Biotechnol"},{"key":"1067_CR32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.cels.2021.10.007","volume":"13","author":"W Stallaert","year":"2022","unstructured":"Stallaert W, Kedziora KM, Taylor CD, Zikry TM, Ranek JS, Sobon HK, et al. The structure of the human cell cycle. Cell Syst. 2022;13:230\u201340.e3.","journal-title":"Cell Syst"},{"key":"1067_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-293","volume":"15","author":"P Bardou","year":"2014","unstructured":"Bardou P, Mariette J, Escudi\u00e9 F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinforma. 2014;15:293.","journal-title":"BMC Bioinforma"},{"key":"1067_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.stem.2019.01.001","volume":"24","author":"CTJ van Velthoven","year":"2019","unstructured":"van Velthoven CTJ, Rando TA. Stem cell quiescence: dynamism, restraint, and cellular idling. Cell Stem Cell. 2019;24:213\u201325.","journal-title":"Cell Stem Cell"},{"key":"1067_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/OTT.S447319","volume":"17","author":"J Chen","year":"2024","unstructured":"Chen J, Zhu H, Chen S, Mi H. Apolipoprotein E is a potential biomarker for predicting cancer prognosis and is correlated with immune infiltration. OncoTargets Ther. 2024;17:199\u2013214.","journal-title":"OncoTargets Ther"},{"key":"1067_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/JTO.0b013e3181d5e554","volume":"5","author":"HJ Lee","year":"2010","unstructured":"Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol. 2010;5:649\u201357.","journal-title":"J Thorac Oncol"},{"key":"1067_CR37","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/jcp.27581","volume":"234","author":"V Tarhriz","year":"2019","unstructured":"Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol. 2019;234:2134\u201342.","journal-title":"J Cell Physiol"},{"key":"1067_CR38","doi-asserted-by":"crossref","unstructured":"Mosaddeghzadeh N, Ahmadian MR. The RHO Family GTPases: mechanisms of regulation and signaling. Cells 2021;10:1831.","DOI":"10.3390\/cells10071831"},{"key":"1067_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.molcel.2016.10.016","volume":"64","author":"F Gualdrini","year":"2016","unstructured":"Gualdrini F, Esnault C, Horswell S, Stewart A, Matthews N, Treisman R. SRF co-factors control the balance between cell proliferation and contractility. Mol cell. 2016;64:1048\u201361.","journal-title":"Mol cell"},{"key":"1067_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1028","volume":"10","author":"KM Pawelec","year":"2022","unstructured":"Pawelec KM, Varnum M, Harkema JR, Auerbach B, Larsen SD, Neubig RR. Prevention of bleomycin-induced lung fibrosis via inhibition of the MRTF\/SRF transcription pathway. Pharm Res Perspect. 2022;10:e01028.","journal-title":"Pharm Res Perspect"},{"key":"1067_CR41","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1101\/gad.2011311","volume":"25","author":"MM Klosinska","year":"2011","unstructured":"Klosinska MM, Crutchfield CA, Bradley PH, Rabinowitz JD, Broach JR. Yeast cells can access distinct quiescent states. Genes Dev. 2011;25:336\u201349.","journal-title":"Genes Dev"},{"key":"1067_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat5685","volume":"4","author":"K Sajiki","year":"2018","unstructured":"Sajiki K, Tahara Y, Uehara L, Sasaki T, Pluskal T, Yanagida M. Genetic regulation of mitotic competence in G(0) quiescent cells. Sci Adv. 2018;4:eaat5685.","journal-title":"Sci Adv"},{"key":"1067_CR43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1146\/annurev.biochem.052308.114844","volume":"78","author":"ET Powers","year":"2009","unstructured":"Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem. 2009;78:959\u201391.","journal-title":"Annu Rev Biochem"},{"key":"1067_CR44","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866\u20138.","journal-title":"Bioinformatics"},{"key":"1067_CR45","doi-asserted-by":"crossref","unstructured":"Sannino S, Yates ME, Schurdak ME, Oesterreich S, Lee AV, Wipf P, et al. Unique integrated stress response sensors regulate cancer cell susceptibility when Hsp70 activity is compromised. Elife. 2021;10:e64977.","DOI":"10.7554\/eLife.64977"},{"key":"1067_CR46","doi-asserted-by":"publisher","first-page":"10534","DOI":"10.1093\/nar\/gkx711","volume":"45","author":"H Hoffmeister","year":"2017","unstructured":"Hoffmeister H, Fuchs A, Erdel F, Pinz S, Gr\u00f6bner-Ferreira R, Bruckmann A, et al. CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. Nucleic Acids Res. 2017;45:10534\u201354.","journal-title":"Nucleic Acids Res"},{"key":"1067_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/BJ20150030","volume":"468","author":"V Kolla","year":"2015","unstructured":"Kolla V, Naraparaju K, Zhuang T, Higashi M, Kolla S, Blobel GA, et al. The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex. Biochem J. 2015;468:345\u201352.","journal-title":"Biochem J"},{"key":"1067_CR48","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/sj.onc.1206211","volume":"22","author":"PM Thompson","year":"2003","unstructured":"Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene. 2003;22:1002\u201311.","journal-title":"Oncogene"},{"key":"1067_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mod.2013.10.005","volume":"131","author":"T Zhuang","year":"2014","unstructured":"Zhuang T, Hess RA, Kolla V, Higashi M, Raabe TD, Brodeur GM. CHD5 is required for spermiogenesis and chromatin condensation. Mech Dev. 2014;131:35\u201346.","journal-title":"Mech Dev"},{"key":"1067_CR50","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1093\/nar\/gkt035","volume":"41","author":"K G\u00fcnther","year":"2013","unstructured":"G\u00fcnther K, Rust M, Leers J, Boettger T, Scharfe M, Jarek M, et al. Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res. 2013;41:3010\u201321.","journal-title":"Nucleic Acids Res"},{"key":"1067_CR51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1128\/MCB.26.3.843-851.2006","volume":"26","author":"X Le Guezennec","year":"2006","unstructured":"Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers WA, Cohen A, Lasonder E, et al. MBD2\/NuRD and MBD3\/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 2006;26:843\u201351.","journal-title":"Mol Cell Biol"},{"key":"1067_CR52","doi-asserted-by":"publisher","first-page":"15853","DOI":"10.1074\/jbc.M115.707018","volume":"291","author":"JK Low","year":"2016","unstructured":"Low JK, Webb SR, Silva AP, Saathoff H, Ryan DP, Torrado M, et al. CHD4 is a peripheral component of the nucleosome remodeling and deacetylase complex. J Biol Chem. 2016;291:15853\u201366.","journal-title":"J Biol Chem"},{"key":"1067_CR53","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.2174\/09298673113209990191","volume":"21","author":"H Rajak","year":"2014","unstructured":"Rajak H, Singh A, Raghuwanshi K, Kumar R, Dewangan PK, Veerasamy R, et al. A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity. Curr Med Chem. 2014;21:2642\u201364.","journal-title":"Curr Med Chem"},{"key":"1067_CR54","doi-asserted-by":"crossref","unstructured":"Wilczy\u0144ski JR, Wilczy\u0144ski M, Paradowska E. Cancer stem cells in ovarian cancer-a source of tumor success and a challenging target for novel therapies. Int J Mol Sci. 2022;23:2496.","DOI":"10.3390\/ijms23052496"},{"key":"1067_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","volume":"1","author":"JM Wagner","year":"2010","unstructured":"Wagner JM, Hackanson B, L\u00fcbbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet. 2010;1:117\u201336.","journal-title":"Clin Epigenet"},{"key":"1067_CR56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194\u2013202.","journal-title":"Nat Rev Cancer"},{"key":"1067_CR57","first-page":"8492","volume":"61","author":"PN Munster","year":"2001","unstructured":"Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001;61:8492\u20137.","journal-title":"Cancer Res"},{"key":"1067_CR58","first-page":"187","volume":"15","author":"N Komatsu","year":"2006","unstructured":"Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep. 2006;15:187\u201391.","journal-title":"Oncol Rep"},{"key":"1067_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-014-0112-x","volume":"14","author":"Z Liu","year":"2014","unstructured":"Liu Z, Tong Y, Liu Y, Liu H, Li C, Zhao Y, et al. Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms. Cancer Cell Int. 2014;14:112.","journal-title":"Cancer Cell Int"},{"key":"1067_CR60","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1002\/cncr.26073","volume":"117","author":"MY Chen","year":"2011","unstructured":"Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2\/M arrest, and autophagy. Cancer. 2011;117:4424\u201338.","journal-title":"Cancer"},{"key":"1067_CR61","doi-asserted-by":"publisher","first-page":"e79781","DOI":"10.1371\/journal.pone.0079781","volume":"8","author":"S Chen","year":"2013","unstructured":"Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One. 2013;8:e79781.","journal-title":"PLoS One"},{"key":"1067_CR62","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1038\/onc.2013.482","volume":"33","author":"A Newbold","year":"2014","unstructured":"Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW. The role of p21(waf1\/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the E\u03bc-myc model of B-cell lymphoma. Oncogene. 2014;33:5415\u201323.","journal-title":"Oncogene"},{"key":"1067_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2807-y","volume":"16","author":"I Hrgovic","year":"2016","unstructured":"Hrgovic I, Doll M, Kleemann J, Wang X-F, Zoeller N, Pinter A, et al. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer. 2016;16:763.","journal-title":"BMC Cancer"},{"key":"1067_CR64","doi-asserted-by":"crossref","unstructured":"Mrakovcic M, Kleinheinz J, Fr\u00f6hlich LF. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. Int J Mol Sci 2019;20:2415.","DOI":"10.3390\/ijms20102415"},{"key":"1067_CR65","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1091\/mbc.11.6.2069","volume":"11","author":"L Qiu","year":"2000","unstructured":"Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell. 2000;11:2069\u201383.","journal-title":"Mol Biol Cell"},{"key":"1067_CR66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-16-0482","volume":"16","author":"AJ Haak","year":"2017","unstructured":"Haak AJ, Appleton KM, Lisabeth EM, Misek SA, Ji Y, Wade SM, et al. Pharmacological inhibition of myocardin-related transcription factor pathway blocks lung metastases of RhoC-overexpressing melanoma. Mol Cancer Therapeutics. 2017;16:193\u2013204.","journal-title":"Mol Cancer Therapeutics"},{"key":"1067_CR67","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10637-008-9131-6","volume":"26","author":"J Vansteenkiste","year":"2008","unstructured":"Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest N Drugs. 2008;26:483\u20138.","journal-title":"Invest N Drugs"},{"key":"1067_CR68","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","volume":"27","author":"E Galanis","year":"2009","unstructured":"Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009;27:2052\u20138.","journal-title":"J Clin Oncol"},{"key":"1067_CR69","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","volume":"109","author":"SC Modesitt","year":"2008","unstructured":"Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182\u20136.","journal-title":"Gynecol Oncol"},{"key":"1067_CR70","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/IGC.0b013e31825736fd","volume":"22","author":"DS Dizon","year":"2012","unstructured":"Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R, et al. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer. 2012;22:979\u201386.","journal-title":"Int J Gynecol Cancer"},{"key":"1067_CR71","doi-asserted-by":"crossref","unstructured":"Dumbrava MG, Ismail WM, Sandoval L, Mazzone A, Aalam SMM, Ritting ML, et al. Single cell resolution of an epigenetic signature of persister tumor cells. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2025.04.16.649175v1 (2025).","DOI":"10.1101\/2025.04.16.649175"},{"key":"1067_CR72","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1021\/pr4004079","volume":"12","author":"Q Wu","year":"2013","unstructured":"Wu Q, Xu W, Cao L, Li X, He T, Wu Z, et al. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells. J Proteome Res. 2013;12:4064\u201373.","journal-title":"J Proteome Res"},{"key":"1067_CR73","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1074\/mcp.M113.037127","volume":"13","author":"ME Sardiu","year":"2014","unstructured":"Sardiu ME, Smith KT, Groppe BD, Gilmore JM, Saraf A, Egidy R, et al. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network. Mol Cell Proteom. 2014;13:3114\u201325.","journal-title":"Mol Cell Proteom"},{"key":"1067_CR74","first-page":"45","volume":"24","author":"EM Lee","year":"2009","unstructured":"Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med. 2009;24:45\u201350.","journal-title":"Int J Mol Med"},{"key":"1067_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/srep09520","volume":"5","author":"Q Wu","year":"2015","unstructured":"Wu Q, Cheng Z, Zhu J, Xu W, Peng X, Chen C, et al. Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep. 2015;5:9520.","journal-title":"Sci Rep"},{"key":"1067_CR76","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.chembiol.2013.09.020","volume":"20","author":"XJ Di","year":"2013","unstructured":"Di XJ, Han DY, Wang YJ, Chance MR, Mu TW. SAHA enhances Proteostasis of epilepsy-associated \u03b11(A322D)\u03b22\u03b32 GABA(A) receptors. Chem Biol. 2013;20:1456\u201368.","journal-title":"Chem Biol"},{"key":"1067_CR77","doi-asserted-by":"crossref","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12:265.","DOI":"10.3390\/cancers12020265"},{"key":"1067_CR78","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VTM, Yoon S-S, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195\u2013206.","journal-title":"Lancet Oncol"},{"key":"1067_CR79","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","volume":"14","author":"M Dimopoulos","year":"2013","unstructured":"Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013;14:1129\u201340.","journal-title":"Lancet Oncol"},{"key":"1067_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0154-8","volume":"9","author":"JL Kaufman","year":"2019","unstructured":"Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, et al. Combining carfilzomib and panobinostat to treat relapsed\/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019;9:3.","journal-title":"Blood Cancer J"},{"key":"1067_CR81","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s10637-011-9766-6","volume":"30","author":"M Millward","year":"2012","unstructured":"Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest N Drugs. 2012;30:2303\u201317.","journal-title":"Invest N Drugs"},{"key":"1067_CR82","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10637-013-0035-8","volume":"32","author":"DA Deming","year":"2014","unstructured":"Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, et al. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest N Drugs. 2014;32:323\u20139.","journal-title":"Invest N Drugs"},{"key":"1067_CR83","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41418-019-0292-y","volume":"26","author":"F Nazio","year":"2019","unstructured":"Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019;26:690\u2013702.","journal-title":"Cell Death Differ"},{"key":"1067_CR84","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML, et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell. 2021;184:226\u201342.e21.","journal-title":"Cell"},{"key":"1067_CR85","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neo.2019.06.005","volume":"21","author":"MR Ward Rashidi","year":"2019","unstructured":"Ward Rashidi MR, Mehta P, Bregenzer M, Raghavan S, Fleck EM, Horst EN, et al. Engineered 3D model of cancer stem cell enrichment and chemoresistance. Neoplasia. 2019;21:822\u201336.","journal-title":"Neoplasia"},{"key":"1067_CR86","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H. g:Profiler\u2014interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51:W207\u2013W12.","journal-title":"Nucleic Acids Res"},{"key":"1067_CR87","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/bioinformatics\/btu314","volume":"30","author":"GG Faust","year":"2014","unstructured":"Faust GG, Hall IM. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics. 2014;30:2503\u20135.","journal-title":"Bioinformatics"},{"key":"1067_CR88","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ram\u00edrez","year":"2016","unstructured":"Ram\u00edrez F, Ryan DP, Gr\u00fcning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44:W160\u20135.","journal-title":"Nucleic Acids Res"},{"key":"1067_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4559-3","volume":"19","author":"J Ou","year":"2018","unstructured":"Ou J, Liu H, Yu J, Kelliher MA, Castilla LH, Lawson ND, et al. ATACseqQC: a Bioconductor package for post-alignment quality assessment of ATAC-seq data. BMC Genom. 2018;19:169.","journal-title":"BMC Genom"},{"key":"1067_CR90","unstructured":"Stark R, Brown G. Diff Bind: diff erential binding analysis of ChIP-Seq peak data. Bioconductor. 2018. https:\/\/bioconductor.org\/packages\/release\/bioc\/vignettes\/DiffBind\/inst\/doc\/DiffBind.pdf."},{"key":"1067_CR91","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/bioinformatics\/btv145","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu G, Wang LG, He QY. ChIPseeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 2015;31:2382\u20133.","journal-title":"Bioinformatics"},{"key":"1067_CR92","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/C5MB00663E","volume":"12","author":"G Yu","year":"2016","unstructured":"Yu G, He QY. ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2016;12:477\u20139.","journal-title":"Mol Biosyst"},{"key":"1067_CR93","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41416-018-0267-7","volume":"119","author":"CH Beckwitt","year":"2018","unstructured":"Beckwitt CH, Clark AM, Ma B, Whaley D, Oltvai ZN, Wells A. Statins attenuate outgrowth of breast cancer metastases. Br J Cancer. 2018;119:1094\u2013105.","journal-title":"Br J Cancer"},{"key":"1067_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.676135","volume":"11","author":"AM Clark","year":"2021","unstructured":"Clark AM, Heusey HL, Griffith LG, Lauffenburger DA, Wells A. IP-10 (CXCL10) can trigger emergence of dormant breast cancer cells in a metastatic liver microenvironment. Front Oncol. 2021;11:676135.","journal-title":"Front Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01067-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01067-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01067-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:02:27Z","timestamp":1787731347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01067-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":94,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01067-y","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}